EUR 3.85
(2.67%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 15.62 Million EUR | -102.8% |
2022 | 11.3 Million EUR | -42.16% |
2021 | 19.54 Million EUR | -4.81% |
2020 | 20.53 Million EUR | -8.57% |
2019 | 22.45 Million EUR | -36.73% |
2018 | 35.49 Million EUR | -41.09% |
2017 | 60.25 Million EUR | -9.26% |
2016 | 66.4 Million EUR | 10.89% |
2015 | 59.88 Million EUR | 254.27% |
2014 | 16.9 Million EUR | -23.31% |
2013 | 22.04 Million EUR | -0.35% |
2012 | 22.11 Million EUR | 207.51% |
2011 | 7.19 Million EUR | -35.15% |
2010 | 11.09 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 9.46 Million EUR | 0.0% |
2023 Q2 | 86 Thousand EUR | -84.28% |
2023 Q3 | 2.19 Million EUR | 2450.0% |
2023 Q4 | -402 Thousand EUR | -118.33% |
2023 Q1 | 546.99 Thousand EUR | 469.79% |
2023 FY | -316 Thousand EUR | -102.8% |
2022 Q1 | 5.36 Million EUR | 2253.95% |
2022 Q2 | 82 Thousand EUR | -98.47% |
2022 Q3 | 1.36 Million EUR | 1567.68% |
2022 Q4 | 96 Thousand EUR | -92.98% |
2022 FY | 11.3 Million EUR | -42.16% |
2021 Q1 | 279.49 Thousand EUR | 535.23% |
2021 Q3 | 1 Million EUR | 456.94% |
2021 Q4 | 228 Thousand EUR | -77.26% |
2021 FY | 19.54 Million EUR | -4.81% |
2021 Q2 | 180 Thousand EUR | -35.6% |
2020 FY | 20.53 Million EUR | -8.57% |
2020 Q1 | 391.49 Thousand EUR | 276.44% |
2020 Q2 | 148 Thousand EUR | -62.2% |
2020 Q4 | 44 Thousand EUR | -87.46% |
2020 Q3 | 351 Thousand EUR | 137.16% |
2019 Q2 | 129 Thousand EUR | -60.85% |
2019 FY | 22.45 Million EUR | -36.73% |
2019 Q4 | 104 Thousand EUR | 54.07% |
2019 Q3 | 67.5 Thousand EUR | -47.67% |
2019 Q1 | 329.49 Thousand EUR | -92.52% |
2018 Q1 | 169.5 Thousand EUR | -50.22% |
2018 Q4 | 4.4 Million EUR | 0.0% |
2018 FY | 35.49 Million EUR | -41.09% |
2018 Q3 | 4.4 Million EUR | 2500.59% |
2018 Q2 | 169.5 Thousand EUR | 0.0% |
2017 FY | 60.25 Million EUR | -9.26% |
2017 Q4 | 340.5 Thousand EUR | 0.0% |
2017 Q3 | 340.5 Thousand EUR | -19.79% |
2017 Q2 | 424.5 Thousand EUR | 0.0% |
2017 Q1 | 424.5 Thousand EUR | 39.87% |
2016 Q2 | 382.49 Thousand EUR | 0.0% |
2016 Q3 | 303.49 Thousand EUR | -20.65% |
2016 Q1 | 382.49 Thousand EUR | 19.72% |
2016 Q4 | 303.49 Thousand EUR | 0.0% |
2016 FY | 66.4 Million EUR | 10.89% |
2015 Q4 | 319.5 Thousand EUR | 0.0% |
2015 FY | 59.88 Million EUR | 254.27% |
2015 Q3 | 319.5 Thousand EUR | 38.01% |
2015 Q2 | 231.49 Thousand EUR | 0.0% |
2015 Q1 | 231.49 Thousand EUR | -39.08% |
2014 Q1 | 135.49 Thousand EUR | 22.62% |
2014 Q3 | 379.99 Thousand EUR | 180.44% |
2014 Q4 | 379.99 Thousand EUR | 0.0% |
2014 FY | 16.9 Million EUR | -23.31% |
2014 Q2 | 135.49 Thousand EUR | 0.0% |
2013 Q1 | 142.5 Thousand EUR | 15.38% |
2013 Q2 | 142.5 Thousand EUR | 0.0% |
2013 Q3 | 110.49 Thousand EUR | -22.46% |
2013 Q4 | 110.49 Thousand EUR | 0.0% |
2013 FY | 22.04 Million EUR | -0.35% |
2012 FY | 22.11 Million EUR | 207.51% |
2012 Q4 | 123.5 Thousand EUR | 0.0% |
2012 Q3 | 123.5 Thousand EUR | 0.0% |
2011 FY | 7.19 Million EUR | -35.15% |
2010 FY | 11.09 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -274.168% |
ABIVAX Société Anonyme | 127.37 Million EUR | 87.73% |
Aelis Farma SA | 18.81 Million EUR | 16.951% |
Biophytis S.A. | 14.33 Million EUR | -9.042% |
Advicenne S.A. | 8.21 Million EUR | -90.25% |
genOway Société anonyme | 16.73 Million EUR | 6.627% |
IntegraGen SA | 5.35 Million EUR | -191.994% |
Medesis Pharma S.A. | 1.56 Million EUR | -898.931% |
Neovacs S.A. | 10.34 Million EUR | -51.099% |
NFL Biosciences SA | 4.37 Million EUR | -257.287% |
Plant Advanced Technologies SA | 2.76 Million EUR | -465.275% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -809.739% |
Sensorion SA | 27.05 Million EUR | 42.23% |
Theranexus Société Anonyme | 3 Million EUR | -420.102% |
TME Pharma N.V. | 5.49 Million EUR | -184.319% |
Valbiotis SA | 9.86 Million EUR | -58.365% |
TheraVet SA | 1.64 Million EUR | -850.488% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | 23.086% |
DBV Technologies S.A. | 89.4 Million EUR | 82.519% |
Genfit S.A. | 54.8 Million EUR | 71.482% |
GeNeuro SA | 14.35 Million EUR | -8.858% |
Innate Pharma S.A. | 64.57 Million EUR | 75.795% |
Inventiva S.A. | 120.18 Million EUR | 86.996% |
MaaT Pharma SA | 21.59 Million EUR | 27.637% |
MedinCell S.A. | 32.92 Million EUR | 52.527% |
Nanobiotix S.A. | 58.92 Million EUR | 73.477% |
OSE Immunotherapeutics SA | 23.58 Million EUR | 33.745% |
Poxel S.A. | 28.76 Million EUR | 45.667% |
GenSight Biologics S.A. | 32.66 Million EUR | 52.146% |
Transgene SA | 31.23 Million EUR | 49.957% |
Valneva SE | 134.92 Million EUR | 88.416% |